Results 1 to 10 of about 3,869 (167)

Clinical Characteristics and Outcomes of 1894 Women with Peripartum Cardiomyopathy Treated with and Without Levosimendan in Germany [PDF]

Journal of Cardiovascular Development and Disease
Background: Peripartum cardiomyopathy (PPCM) is a rare form of heart failure occurring during the last month of pregnancy or within five months postpartum.
Jan A. Kloka, Alexandra Popescu, Benjamin Friedrichson, Thomas Jasny, Lea V. Blum, Stephanie Noone, Armin Flinspach, Peter Kranke, Kai Zacharowski, Vanessa Neef   +9 more
doaj   +2 more sources

Weaning from invasive ventilation with levosimendan (WEANLESS): study protocol for a multicentre randomised clinical trial [PDF]

BMJ Open
Background Prolonged weaning from invasive mechanical ventilation is a major challenge in critically ill patients failing a spontaneous breathing trial. Levosimendan, a calcium sensitiser, has been shown to improve respiratory muscle function.
Marcus J Schultz, Nicole G M Hunfeld, Ary Serpa Neto, Leo Heunks, Esther De Leijer, Charlotte Hofma, Jonne Doorduin   +6 more
doaj   +2 more sources

The Coadministration of Levosimendan and Exenatide Offers a Significant Cardioprotective Effect to Isolated Rat Hearts against Ischemia/Reperfusion Injury

Journal of Cardiovascular Development and Disease, 2022
(1) Background: The present study aims to investigate the effect of administration of Levosimendan and Exenatide in various concentrations, as well as of the coadministration of those agents in an ischemia–reperfusion injury isolated heart model.
Vasileios Leivaditis, Efstratios Koletsis, Nikolaos Tsopanoglou, Nikolaos Charokopos, Cristian D’Alessandro, Konstantinos Grapatsas, Efstratios Apostolakis, Effrosyni Choleva, Maria Plota, Andreas Emmanuil, Manfred Dahm, Dimitrios Dougenis   +11 more
doaj   +1 more source

Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function

Indian Heart Journal, 2021
To assess the clinical outcomes of levosimendan and dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function in Indian scenario.
Basil John, Pharm D, Mariya Babu, Pharm D, Sandramol shaji, Pharm D, Suja Abraham, Jabir Abdullakutty   +4 more
doaj   +1 more source

Use of levosimendan combined with Shenfu injection to treat acute heart failure patients with hypotension: a prospective randomized controlled single-blind study

BMC Cardiovascular Disorders, 2022
Background Levosimendan can improve clinical symptoms and the cardiorenal rescue success rate, and stabilize hemodynamic parameters in individuals suffering from acute decompensated heart failure.
Miaomiao Li, Yue Zhang, Qianli Wan, Yiou Li, Tianzhen Qu, Fang Yuan   +5 more
doaj   +1 more source

Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?

European Radiology Experimental, 2021
Background We investigated whether levosimendan prevents contrast medium nephrotoxicity with glycerol aggravation in rats. Methods Forty-eight Wistar albino rats were assigned to eight groups (n = 6 × 8).
Irmak Durur-Subasi, Duygu Kose, Muhammed Yayla, Busra Sirin, Adem Karaman, Ilknur Calik, Fatih Alper   +6 more
doaj   +1 more source

The Effects of the Levosimendan Metabolites OR-1855 and OR-1896 on Endothelial Pro-Inflammatory Responses

Biomedicines, 2023
The calcium sensitizer levosimendan is used for the treatment of acute decompensated heart failure. A small portion (4–7%) of levosimendan is metabolized to the pharmacologically active metabolite OR-1896 via the inactive intermediate OR-1855.
Hannah Kipka, Rebecca Schaflinger, Roland Tomasi, Kristin Pogoda, Hanna Mannell   +4 more
doaj   +1 more source

PERIOPERATIVE USE OF LEVOSIMENDAN IN PATIENTS WITH SEVERE LEFT VENTRICULAR DYSFUNCTION UNDERGOING CARDIAC SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS [PDF]

Ain Shams Medical Journal, 2022
Background: Levosimendan is a calcium-sensitizing ionodilator. However, the current level of clinical evidence is insufficient to determine the clinical value of levosimendan in patients with severe left ventricular dysfunction subjected to cardiac ...
Ramy Reda, Ahmed Fouad, Osama Abd Elhamed, Ahmed Mansour   +3 more
doaj   +1 more source

Influence of timing of Levosimendan administration on outcomes in cardiac surgery

Frontiers in Cardiovascular Medicine, 2023
PurposeThough a subgroup analysis has shown improved survival for patients suffering severely reduced ventricular function undergoing coronary artery bypass grafting, RCTs were not able to demonstrate overall beneficial effects of perioperative ...
Fridtjof Schiefenhövel, Fridtjof Schiefenhövel, Fridtjof Schiefenhövel, Christian Berger, Liubov Penkova, Herko Grubitzsch, Bernhard Haller, Alexander Meyer, Alexander Meyer, Matthias Heringlake, Michael Sander, Joachim M. Erb, Felix Balzer, Sascha Treskatsch   +13 more
doaj   +1 more source

Preconditioning with levosimendan reduces postoperative low cardiac output in moderate-severe systolic dysfunction patients who will undergo elective coronary artery bypass graft surgery: a cost-effective strategy

Journal of Cardiothoracic Surgery, 2020
Background Patients with moderate-severe systolic dysfunction undergoing coronary artery bypass graft have a higher incidence of postoperative low cardiac output. Preconditioning with levosimendan may be a useful strategy to prevent this complication. In
Juan José Jiménez-Rivera, Andrea Álvarez-Castillo, Jorge Ferrer-Rodríguez, José Luis Iribarren-Sarrías, Martín Jesús García-González, Pablo Jorge-Pérez, Juan Lacalzada-Almeida, Rosalía Pérez-Hernández, Javier Montoto-López, Rafael Martínez-Sanz   +9 more
doaj   +1 more source